U.S. Markets closed

Biogen Won't Disavow Its Alzheimer's Goal — So What's Next For Growth?

ALLISON GATLIN
Biogen Won't Disavow Its Alzheimer's Goal — So What's Next For Growth?

Biogen could pivot to inflammation following its high-profile Alzheimer's disease treatment flop, an analyst said Wednesday after the biotech reported an "operationally sound quarter."